Responsive image

Common name

N-ethylpropan-2-amine

IUPAC name

N-ethylpropan-2-amine

SMILES

C(C)(C)NCC

Common name

N-ethylpropan-2-amine

IUPAC name

N-ethylpropan-2-amine

SMILES

C(C)(C)NCC

INCHI

InChI=1S/C5H13N/c1-4-6-5(2)3/h5-6H,4H2,1-3H3

FORMULA

C5H13N

Responsive image

Common name

N-ethylpropan-2-amine

IUPAC name

N-ethylpropan-2-amine





Molecular weight

87.163

clogP

0.511

clogS

-1.443

Frequency

0.0045





HBond Acceptor

0

HBond Donor

1

Total Polar
Surface Area

12.03

Number of Rings

0

Rotatable Bond

2

Drug ID Common name Structure CAS Compound class Therapeutic area
FDBD00081 Indecainide Responsive image Anti-Arrhythmia Agents; Sodium Channel Blockers; For the treatment of life-threatening dysrhythmias and sustained ventricular tachycardia.
FDBD00167 Disopyramide Responsive image Anti-Arrhythmia Agents; Voltage-Gated Sodium Channel Blockers; Cardiovascular System; Antiarrhythmics, Class I and Iii; Cardiac Therapy; Antiarrythmics, Class I and Iii; Antiarrhythmics, Class Ia; CYP3A4 Inhibitors; For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias. It is a Class Ia antiarrhythmic drug.
FDBD00272 Ethopropazine Responsive image Muscarinic Antagonists; Histamine Antagonists; Adrenergic Antagonists; Antidyskinetics; Nervous System; Anti-Parkinson Drugs; Anticholinergics; Tertiary Amines; For use in the treatment of Parkinson's disease and also used to control severe reactions to certain medicines such as reserpine.
FDBD00570 Tamsulosin Responsive image Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Genito Urinary System and Sex Hormones; Drugs Used in Benign Prostatic Hypertrophy; Urological Agents; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; Used in the treatment of signs and symptoms of benign prostatic hyperplasia (reduction in urinary obstruction and relief of associated manifestations such as hesitancy, terminal dribbling of urine, interrupted or weak stream..etc.).
FDBD00702 Dobutamine Responsive image Sympathomimetics; Cardiotonic Agents; Adrenergic beta-1 Receptor Agonists; Cardiovascular System; Cardiac Therapy; Adrenergic and Dopaminergic Agents; Cardiac Stimulants Excl. Cardiac Glycosides; Beta2 Agonists; For inotropic support in the short- term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.
FDBD00889 Tolterodine Responsive image Muscarinic Antagonists; Anti-Incontinence Agents; Antispasmodics; Muscle Relaxants, Genitourinary; Genito Urinary System and Sex Hormones; Drugs for Urinary Frequency and Incontinence; Cytochrome P-450 CYP2C9 Inhibitors; Urological Agents; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
FDBD01037 Dexfenfluramine Responsive image Serotonin Uptake Inhibitors; Anti-Obesity Agents; Serotonin Receptor Agonists; Alimentary Tract and Metabolism; Centrally Acting Antiobesity Products; Antiobesity Preparations, Excl. Diet Products; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C19 Inducers; CYP2A6 Inhibitors; CYP2A6 Inhibitors (strong); CYP2A6 Inhibitors (moderate); CYP2A6 Inducers; CYP2A6 Inducers (strong); CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP2E1 Inhibitors; CYP2E1 Inducers; CYP2E1 Inducers (strong); For the management of obesity including weight loss and maintenance of weight loss in patients on a reduced calorie diet.
FDBD01216 Fenethylline Responsive image Nervous System; Psychoanaleptics; Centrally Acting Sympathomimetics; Psychostimulants, Agents Used for Adhd and Nootropics;
FDBD01385 Silodosin Responsive image Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Genito Urinary System and Sex Hormones; Drugs Used in Benign Prostatic Hypertrophy; Urological Agents; CYP3A4 Inhibitors; Treatment for symptomatic relief of benign prostatic hyperplasia .
FDBD01442 Fesoterodine Responsive image Muscarinic Antagonists; Anti-Incontinence Agents; Antispasmodics; Muscle Relaxants, Genitourinary; Genito Urinary System and Sex Hormones; Drugs for Urinary Frequency and Incontinence; Urological Agents; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
13 , 2
FRAGNAME PDBID SIMILIRITY XSCORE SMILE HAC
3acx_ligand_2_15.mol2 3acx 1 -6.07 C(C)(C)[NH2+]CC 6
4eki_ligand_3_100.mol2 4eki 1 -6.04 C(C)(C)[NH2+]CC 6
4eki_ligand_4_195.mol2 4eki 1 -6.04 CC[N@H+](C)C(C)C 7
2c4f_ligand_2_30.mol2 2c4f 1 -5.89 [NH2+](C(C)C)C(C)C 7
4wvl_ligand_3_340.mol2 4wvl 1 -5.85 C(C)(C)[NH2+]CC 6
4wvl_ligand_4_1325.mol2 4wvl 1 -5.80 CC[N@H+](C)C(C)C 7
2fwz_ligand_2_0.mol2 2fwz 1 -5.47 CC[NH2+]C(C)C 6
3myg_ligand_3_25.mol2 3myg 1 -5.36 C(C)[N@H+](C)C(C)C 7
4bhf_ligand_2_1.mol2 4bhf 0.857143 -6.47 [N+](C)(C)(C)C(C)C 7
280 , 29